Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories announces the launch of Palonosetron Hydrochloride Injection in the U.S. Market".

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

Reddy's Laboratories announces the launch of

Hydrochloride Injection in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. March 26, 2018-

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Palonosetron

Hydrochloride Injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent generic version of ALOXI (palonosetron

hydrochloride) Injection approved by the U.S. Food and Drug Administration (USFDA).

The ALOXI brand and generic had U.S. sales

of approximately $446 million MAT for the most recent twelve months ending in January 2018 according to IMS Health*.

Dr. Reddy's Palonosetron Hydrochloride Injection is available

in a strength of 0.25 mg/5 mL (free base) in a single-dose vial packaged in a carton containing one vial.

ALOXI is a registered trademark of Helsinn

*IMS National Sales Perspective: Retail and Non-Retail

About Dr. Reddy's: Dr. Reddy's

Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable

and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients,

Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs,

custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are

gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets

across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,

log on to: www.drreddys.com

Disclaimer: This press release may include

statements of future expectations and other forward-looking statements that are based on the management's current views

and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to

differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason

of context, the words "may", "will", "should", "expects", "plans", "intends",

"anticipates", "believes", "estimates", "predicts", "potential", or "continue"

and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from

those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets,

credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events

(ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes

in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization

, including related integration issues.

The company assumes no obligation to update any information